GLP-1) receptor agonists, which are used to treat type 2 diabetes and/or obesity, were linked to vision problems in a small study. Here's what doctors have to say.

Share on Pinterest A drug already used to treat people who have diabetes and/or chronic kidney disease could have added heart disease benefits, too. Richard Drury/Getty Images According to ...

lowering a dose or switching to another medication — an approach called de-intensification. The advent of effective new diabetes drugs — GLP-1 receptor agonists (like Ozempic) and SGLT2 ...

It remained unclear, however, whether physicians should prescribe the drugs, given their known side ... particularly in people with uncontrolled diabetes, and make sure that blood sugar levels are ...

Kidney transplant recipients with type 2 diabetes treated with a new class of anti-obesity drugs were less likely to ...

Women of reproductive age with T2D who have low contraception use take medications that are not recommended for pregnancy.

SGLT-2 inhibitors vs DPP-4 inhibitors were associated with a reduced risk for liver cirrhosis among patients with type 2 diabetes.

or pre-diabetes. However, PBAC concluded semaglutide should not be subsidized through the PBS because it didn't consider the drug cost-effective at the price proposed. PBAC referred to evidence on ...

GLP-1 receptor agonists were initially approved for glycaemic control in type 2 diabetes and, subsequently, for bodyweight loss in obesity. Following large-scale trials demonstrating that some GLP-1 ...

Empagliflozin, which in addition to treating type-2 diabetes, also aids weight loss, and reduces cardiovascular and kidney ...